Showing 4 results for Type of Study: Letter to Editor
, ,
Volume 3, Issue 2 (6-2004)
Abstract
Fatemeh Bandarian, Nazli Namazi, Mohammad Pajouhi, Mohammadreza Amini, Neda Mehrdad, Bagher Larijani,
Volume 20, Issue 1 (1-2021)
Abstract
Endocrinology and Metabolism Research Institute (EMRI) was established in 1993. EMRI has progressed step by step from the beginning and has reached maturity in the last 25 years. EMRI has expanded, advanced in human resources and infrastructures (laboratories and new technologies) and gained first rank in endocrine research in various fields. It has also worked with regional and international organizations such as the World Health Organization (WHO), the International Osteoporosis Foundation (IOF), and the American Clinical Endocrine Society (AACE). This article provides an overview of EMRI activities over a quarter of a century.
Mahin Bndarian, Fatemeh Bandarian,
Volume 23, Issue 5 (12-2023)
Abstract
Sodium-glucose transporter-2 (SGLT-2) inhibitors are a relatively new class of anti-diabetic drugs with potent effect in glycemic control and weight loss, as well as beneficial effects in the prevention and control of cardiac and renal complications in non-pregnant patients with type 2 diabetes. However, there is no enough clear and strong evidence about the beneficial or adverse effect of SGLT-2 inhibitors usage during pregnancy for management of gestational diabetes (GDM) in human. This short letter discusses challenges in application of SGLT-2 inhibitors in management of GDM.
Zahra Hoseini Tavassol, Mona Tamaddon, Hanieh-Sadat Ejtahed, Bagher Larijani,
Volume 25, Issue 5 (12-2025)
Abstract
Desmond et al. (2025) have recently shown that subcutaneous injections of Mycobacterium vaccae ATCC 15483(M. vaccae) in adolescent male mice significantly prevented excessive weight gain and visceral adiposity induced by a Western-style diet. Despite no change in gut microbiota diversity, this intervention lowered hippocampal neuroinflammation markers (Nfkbia, Nlrp3) and anxiety-like behaviors. Since more than one billion people worldwide and about 30% of Iranian population are influenced by obesity, and this disease caused one in eight deaths from noncommunicable diseases in 2024, these microbiome-based strategies could have clinical value. Such approaches that target immunometabolic pathways represent a promising and interdisciplinary strategy that integrates endocrinology, microbiology, and the psychosomatic aspects of metabolic disorders. Nevertheless, M. vaccae media portrayal as an obesity vaccine causes misunderstanding. This treatment reduces, but does not completely hinder, diet-associated weight gain and could not be replaced with healthy diet habits. However, it could be considered as a supplementary approach to reduce the adverse effects of ultra-processed food consumption and could potentially augment existing obesity treatments, such as microbiome-based interventions, pharmaceutical therapies, and bariatric surgery. More extensive clinical trials are required to determine human efficacy, optimal dosing, safety, and integration with current obesity therapies.
